The aim of this study is to look at how the study medicine behaves in participants body and how it is removed from their body. The study compares three different doses of the study medicine in Chinese healthy men. Participant will either get 0.3 mg, 0.9 mg or 1.8 mg NNC0174-0833 which dose participant get is decided by chance. NNC0174-0833 is a new medicine and has not been approved by the Center for Drug Evaluation. We are testing the study medicine to make a medicine that can help people lose weight. Participant will get 1 injection by a study nurse or doctor at the clinic. The injection will be with a needle in a skin fold in the stomach area. The study will last for about 5 months. But participants participation will last about 2 months. Participant will have 8 clinic visits with the study staff. One of these visits will be a 7-day, 6-night stay. At all visits, except the information visit, participant will have blood drawn along with other clinical examinations. Participants will be asked about their health, medical history and habits including mental health.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
24
Participants will either get a single dose of 0.3 mg, 0.9 mg or 1.8 mg NNC0174-0833, administered subcutaneously (s.c., under the skin)
Novo Nordisk Investigational Site
Shanghai, Shanghai Municipality, China
AUC0-∞, NNC0174-0833: The area under the NNC0174-0833 plasma concentration-time curve from time 0 to infinity after a single dose
measured in h·nmol/L
Time frame: From pre-dose (Day 1) to Visit 7 (Day 36)
AUC0-168, NNC0174-0833: The area under the NNC0174-0833 plasma concentration-time curve from time 0 to 168 hours after a single dose
measured in h·nmol/L
Time frame: From pre-dose (Day 1) to Visit 3 (Day 8)
Cmax, NNC0174-0833: The maximum concentration of NNC0174-0833 in plasma
measured in nmol/L
Time frame: From pre-dose (Day 1) to Visit 7 (Day 36)
tmax, NNC0174-0833: The time from dose administration to maximum plasma concentration of NNC0174-0833
measured in hours
Time frame: From pre-dose (Day 1) to Visit 7 (Day 36)
t1/2, NNC0174-0833: The terminal half-life of NNC0174-0833
measured in hours
Time frame: From pre-dose (Day 1) to Visit 7 (Day 36)
CL/FNNC0174-0833: The apparent total plasma clearance of NNC0174-0833
measured in L/h
Time frame: From pre-dose (Day 1) to Visit 7 (Day 36)
Vz/FNNC0174-0833: The apparent volume of distribution of NNC0174-0833 in the terminal phase
measured in L
Time frame: From pre-dose (Day 1) to Visit 7 (Day 36)
Change in body weight
measured in percentage
Time frame: From pre-dose (Day 1) to Visit 7 (Day 36)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.